StockMarketWire.com - Indivior said it had launched in the US a new injectable treatment for schizophrenia.

The once-monthly treatment, Perseris, used an extended-release delivery system to form a depot under the skin following abdominal subcutaneous administration by a healthcare provider.

'Schizophrenia is a complex disease and part of the complexity is that a patient may not recognize that they are ill and therefore not see the need to take medicine,' said chief medical officer Anne Andorn.

'Perseris is a once-monthly injection of a commonly prescribed medication known to reduce symptoms of schizophrenia and does not depend on the patient taking additional oral medication.'


At 1:18pm: [LON:INDV] Indivior Plc share price was +0.55p at 105.3p



Story provided by StockMarketWire.com